KNSA · Kiniksa Pharmaceuticals International, plc
$76.31
+0.52 (+0.69%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$11.72B
Shares
156.05M
Volume · Oct 5
391.56K
Avg daily vol (3M)
602.43K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$75.79
Open$75.58
Day$74.56–76.22
52W close$37.01–80.92
Avg vol 30d533K
Short int3.9M · 2.5% float · 7.2d
Short vol50%
Last earningsJul 28, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 3 wks
filed Jul 28, 2026
call held Jul 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$754.04M
Trailing 12 months
Net income (TTM)
$73.06M
Trailing 12 months
Revenue growth YoY
+55.5%
Year over year
Operating margin
12.4%
Trailing 12 months
P / E (TTM)
83.3
Trailing earnings · reciprocal yield 1.2%
FCF yield
1.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$468.09M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.2%
Year over year · more shares
Price change (1Y)
+102.3%
Trailing year
Short interest
2.5%
Latest settlement · 7.2 days to cover
AI Brief
Q2 FY26 earnings call · Jul 28, 2026
Q2 FY26
TL;DR. Kiniksa reported Q2 ARCALYST net revenue of $243.6M (~55% YoY growth), raised 2026 ARCALYST revenue guidance to $980–$995M from $930–$945M, and announced positive Phase 2 data for KPL-387 with the pivotal Phase 3 PASTORALE trial now enrolling.
Bullish
- + Raised full-year 2026 ARCALYST revenue guidance to $980–$995M from prior $930–$945M
- + KPL-387 Phase 2 showed rapid, sustained efficacy at 300 mg SC monthly, with Phase 3 PASTORALE now enrolling
- + Penetration into multiple-recurrence population grew to ~21% from ~18%, with ~450 new prescribers in Q2
- + Cash position of $525.9M with no debt and expected to remain cash flow positive on an annual basis
Bearish
- − R&D expenses more than doubled YoY to $40.9M as KPL-387 clinical, manufacturing, and preclinical investment ramped
- − SG&A rose to $63.9M from $46.9M YoY on ARCALYST commercialization investment
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+35%
above
Price vs 50-day avg
−2%
below
RSI (14)
48
neutral
MACD trend
Negative
52-week position
88%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+60%
trailing
YTD return
+84%
this year
Relative strength
+48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $77 › 200d $56 — 50d above 200d
Institutional flow
Accumulating
1 of 269 funds reported for Sep 30 · net +20 sh shares
Insider flow
Distributing
Net -$299.1K over 90 days · 100% sells
Short interest
Rising
2.48% of float · ▲ +2.3% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
269 holders — near 2-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+60%
Y/Y
EPS growth
+225%
Y/Y
Free cash flow
$136.4M
Valuation
P/E 82.5
rich
Quant / Vol
risk profile
Volatility
49%
annualized · 1-yr
Max drawdown
−21%
past year
ATR
3.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
Full year 2026 revenue
· full year 2026
Initiated
$980M – $995M
prior FY $677.56M
midpoint +45.7% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+35%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
88%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $77 › 200d $56 — 50d above 200d
Institutional flow
Accumulating
1 of 269 funds reported for Sep 30 · net +20 sh shares
Insider flow
Distributing
Net -$299.1K over 90 days · 100% sells
Short interest
Rising
2.48% of float · ▲ +2.3% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
269 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $37
Now $76 · 88%
Range high $81
vs 200-day avg +35%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KNSA
this stock
Kiniksa Pharmaceuticals International, plc
|
$11.72B | +83.7% | +60.1% | 82.5 | 2.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KNSA | +1.0% | -5.8% | +60.2% | +1.6% | +83.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +1.2% | -5.4% | +48.1% | +0.7% | +70.9% |